FR2909286B1 - Methode d'immunisation contre les 4 serotypes de la dengue - Google Patents

Methode d'immunisation contre les 4 serotypes de la dengue

Info

Publication number
FR2909286B1
FR2909286B1 FR0655255A FR0655255A FR2909286B1 FR 2909286 B1 FR2909286 B1 FR 2909286B1 FR 0655255 A FR0655255 A FR 0655255A FR 0655255 A FR0655255 A FR 0655255A FR 2909286 B1 FR2909286 B1 FR 2909286B1
Authority
FR
France
Prior art keywords
serotypes
dengue
immunization method
method against
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0655255A
Other languages
English (en)
French (fr)
Other versions
FR2909286A1 (fr
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Priority to FR0655255A priority Critical patent/FR2909286B1/fr
Priority to TW096143113A priority patent/TWI400249B/zh
Priority to US11/944,311 priority patent/US7718359B2/en
Priority to ARP070105280A priority patent/AR064009A1/es
Priority to AU2007327367A priority patent/AU2007327367B2/en
Priority to BRPI0718927-3A2A priority patent/BRPI0718927A2/pt
Priority to EP07866551.0A priority patent/EP2099483B1/fr
Priority to JP2009538758A priority patent/JP5269803B2/ja
Priority to CNA2007800439553A priority patent/CN101541344A/zh
Priority to MX2009004223A priority patent/MX2009004223A/es
Priority to KR1020097010676A priority patent/KR20090087890A/ko
Priority to ZA200902540A priority patent/ZA200902540B/xx
Priority to CA002668570A priority patent/CA2668570A1/en
Priority to MYPI20091957A priority patent/MY180698A/en
Priority to PCT/FR2007/052431 priority patent/WO2008065315A1/fr
Publication of FR2909286A1 publication Critical patent/FR2909286A1/fr
Priority to IL198466A priority patent/IL198466A/en
Priority to US12/718,931 priority patent/US20100239612A1/en
Application granted granted Critical
Publication of FR2909286B1 publication Critical patent/FR2909286B1/fr
Priority to IL230052A priority patent/IL230052A0/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0655255A 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue Expired - Fee Related FR2909286B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue
TW096143113A TWI400249B (zh) 2006-12-01 2007-11-14 針對４個登革熱血清型的免疫方法
US11/944,311 US7718359B2 (en) 2006-12-01 2007-11-21 Method of immunization against the 4 serotypes of dengue fever
ARP070105280A AR064009A1 (es) 2006-12-01 2007-11-28 Metodo de inmunizacion contra los 4 serotipos del dengue
MYPI20091957A MY180698A (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
EP07866551.0A EP2099483B1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue
JP2009538758A JP5269803B2 (ja) 2006-12-01 2007-11-30 デング熱の４種の血清型に対する免疫付与のプロトコル
CNA2007800439553A CN101541344A (zh) 2006-12-01 2007-11-30 针对4种登革热血清型的免疫方法
MX2009004223A MX2009004223A (es) 2006-12-01 2007-11-30 Protocolo de inmunizacion contra los 4 serotipos del dengue.
KR1020097010676A KR20090087890A (ko) 2006-12-01 2007-11-30 4 가지 뎅기열 혈청형에 대한 면역화 프로토콜
AU2007327367A AU2007327367B2 (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
CA002668570A CA2668570A1 (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
BRPI0718927-3A2A BRPI0718927A2 (pt) 2006-12-01 2007-11-30 Método de imunização contra os quatro sorotipos da dengue.
PCT/FR2007/052431 WO2008065315A1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue
ZA200902540A ZA200902540B (en) 2006-12-01 2007-11-30 Immunization protocol against the 4 dengue serotypes
IL198466A IL198466A (en) 2006-12-01 2009-04-30 Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines
US12/718,931 US20100239612A1 (en) 2006-12-01 2010-03-05 Method of Immunization Against the 4 Serotypes of Dengue Fever
IL230052A IL230052A0 (en) 2006-12-01 2013-12-19 A method for vaccination against 4 serotypes of dengue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (2)

Publication Number Publication Date
FR2909286A1 FR2909286A1 (fr) 2008-06-06
FR2909286B1 true FR2909286B1 (fr) 2012-06-08

Family

ID=38198298

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0655255A Expired - Fee Related FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue

Country Status (16)

Country Link
US (2) US7718359B2 (enExample)
EP (1) EP2099483B1 (enExample)
JP (1) JP5269803B2 (enExample)
KR (1) KR20090087890A (enExample)
CN (1) CN101541344A (enExample)
AR (1) AR064009A1 (enExample)
AU (1) AU2007327367B2 (enExample)
BR (1) BRPI0718927A2 (enExample)
CA (1) CA2668570A1 (enExample)
FR (1) FR2909286B1 (enExample)
IL (2) IL198466A (enExample)
MX (1) MX2009004223A (enExample)
MY (1) MY180698A (enExample)
TW (1) TWI400249B (enExample)
WO (1) WO2008065315A1 (enExample)
ZA (1) ZA200902540B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2010141386A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
EP2473624B1 (en) * 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
JP2015524421A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
WO2014204892A1 (en) * 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
KR20210071979A (ko) 2018-09-05 2021-06-16 다케다 백신즈 인코포레이티드 뎅기열 백신 단위 용량 및 이의 투여
KR20220049023A (ko) 2019-08-16 2022-04-20 다케다 백신즈 인코포레이티드 뎅기열 및 a형 간염을 예방하기 위한 방법
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
EP1165127B1 (en) 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
ATE526411T1 (de) * 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ES2315221T3 (es) * 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
CN1791433B (zh) 2003-03-24 2010-05-26 斯克里普斯研究学院 抗肿瘤生长的dna疫苗及其使用方法
CA2611954C (en) * 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
JP5197362B2 (ja) * 2005-06-17 2013-05-15 サノフィ・パスツール デング熱セロタイプ１弱毒株
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.

Also Published As

Publication number Publication date
EP2099483A1 (fr) 2009-09-16
IL198466A (en) 2014-01-30
JP5269803B2 (ja) 2013-08-21
JP2010511022A (ja) 2010-04-08
US20080131460A1 (en) 2008-06-05
TW200829599A (en) 2008-07-16
KR20090087890A (ko) 2009-08-18
MY180698A (en) 2020-12-07
IL198466A0 (en) 2011-08-01
FR2909286A1 (fr) 2008-06-06
CA2668570A1 (en) 2008-06-05
IL230052A0 (en) 2014-01-30
WO2008065315A1 (fr) 2008-06-05
TWI400249B (zh) 2013-07-01
US20100239612A1 (en) 2010-09-23
US7718359B2 (en) 2010-05-18
AR064009A1 (es) 2009-03-04
CN101541344A (zh) 2009-09-23
AU2007327367B2 (en) 2013-05-09
AU2007327367A1 (en) 2008-06-05
ZA200902540B (en) 2010-07-28
BRPI0718927A2 (pt) 2014-04-08
EP2099483B1 (fr) 2013-12-25
MX2009004223A (es) 2009-04-30

Similar Documents

Publication Publication Date Title
FR2906724B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
ZA200900155B (en) Method of immunisation against the four serotypes of dengue
EP2318530A4 (en) NEW EPITOP FOR IMMUNIZING AGAINST INFLUENZA VIRUS
EP2227249A4 (en) IMPROVED IMMUNIZING COMPOSITION
LT2351578T (lt) Vakcinų gavimo būdas
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
EP2076221A4 (en) IMPLANT FOR ARTHRODESIS
DK2077287T3 (da) Fremgangsmåde til fremstilling af blødt polyurethanskum
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
EP2173265A4 (en) FAZTENGELENKIMPLANTAT AND RELEVANT PROCEDURES
EP2037738A4 (en) feeding method
EP1780540A4 (en) METHOD FOR THE INVESTIGATION OF UNDERGROUND TUBES
BRPI0819037A2 (pt) "método de fabricar uma bebida"
EP2083845A4 (en) ABLATIVE IMMUNOTHERAPY
NO20050773L (no) Umbilical og fremgangsmate for dens fremstilling
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
EP2305292A4 (en) TRANSDERMAL IMMUNIZER OF S / O TYPE
GB0605247D0 (en) Compositions and methods for immunisation
EP2061506A4 (en) VACCINE COMPOSITION AND IMMUNIZATION PROCEDURE
NO20064595A (no) Titanimplantat og fremgangsmåte for fremstilling derav
ITMI20061848A1 (it) Procedimento per la preparazione di composti feniltetrazolici
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne
EP1904097A4 (en) MALARIA MSP-1 C-TERMINAL REINFORCED SUBUNIT VACCINE
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160831